KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Up 8.7% on Analyst Upgrade

Key Points

• Shares rose 8.7% after Stifel Nicolaus raised its price target to $42 and reiterated a buy rating; the stock traded as high as $18.82 (last $18.635) and the consensus price target is $32.60 ("Moderate Buy").
• $49.1M in EKTERLY revenue was reported during an eight‑month transition period, signaling early commercial execution and serving as a positive fundamental catalyst.
• Insider selling occurred: CEO Benjamin Palleiko and another insider sold shares on Feb. 23, with insiders selling 33,378 shares (about $522,290) in the past three months and insiders now owning 4.3% of the stock.

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) traded up 8.7% during mid-day trading on Thursday after Stifel Nicolaus raised their price target on the stock from $39.00 to $42.00. Stifel Nicolaus currently has a buy rating on the stock. KalVista Pharmaceuticals traded as high as $18.82 and last traded at $18.6350. 837,871 shares traded hands during mid-day trading, a decline of 16% from the average session volume of 1,000,371 shares. The stock had previously closed at $17.14.

A number of other analysts have also recently weighed in on the company. Wall Street Zen upgraded KalVista Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, December 6th. HC Wainwright boosted their target price on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a "buy" rating in a research note on Friday, January 9th. Needham & Company LLC increased their price objective on KalVista Pharmaceuticals from $35.00 to $36.00 and gave the stock a "buy" rating in a report on Wednesday. Weiss Ratings restated a "sell (d-)" rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. Finally, TD Cowen reaffirmed a "buy" rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 3rd. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, KalVista Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $32.60.

Insider Transactions at KalVista Pharmaceuticals

In related news, insider Nicole Sweeny sold 3,975 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $61,890.75. Following the transaction, the insider directly owned 47,003 shares of the company's stock, valued at $731,836.71. The trade was a 7.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Benjamin L. Palleiko sold 10,034 shares of the business's stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $156,229.38. Following the completion of the sale, the chief executive officer owned 442,883 shares in the company, valued at approximately $6,895,688.31. This trade represents a 2.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 33,378 shares of company stock valued at $522,290 in the last three months. 4.30% of the stock is currently owned by insiders.

KalVista Pharmaceuticals News Roundup

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and kept a "buy" rating (implies ~138% upside vs. the referenced $17.64 base), signaling stronger analyst conviction on KalVista's outlook. Stifel Nicolaus raises PT to $42
• Positive Sentiment: Needham & Company raised its price target to $36 and maintains a "buy" rating (~104% upside vs. referenced price), another bullish analyst action supporting the rally. Needham raises PT to $36 TickerReport coverage
• Positive Sentiment: Company reported a strong EKTERLY commercial launch, posting $49.1M in EKTERLY revenue during an eight‑month transition period — this early revenue print validates commercial execution and is a clear positive fundamental catalyst. Earnings call highlights / EKTERLY revenue MSN: EKTERLY revenue
• Neutral Sentiment: Transcripts of the Q1 2025 and eight‑month earnings calls are available for detail on guidance, margins, and commercialization specifics — useful for investors doing deeper due diligence but informational rather than a new catalyst. MSN Q1 2025 transcript Seeking Alpha 8‑month transcript
• Neutral Sentiment: Reported large increases in short interest appear internally inconsistent (values show 0 shares / NaN increases and days‑to‑cover 0.0), suggesting a reporting/data glitch rather than a confirmed shorting pressure signal — monitor for corrected filings.
• Negative Sentiment: Citizens JMP trimmed its price target slightly to $28 (from $29) and rates the stock "market outperform" — a mild negative relative to other, larger upward revisions, but still supportive versus current price. Citizens JMP lowers PT to $28

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of KALV. BNP Paribas Financial Markets boosted its stake in shares of KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company's stock worth $46,000 after acquiring an additional 1,292 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of KalVista Pharmaceuticals during the third quarter worth $55,000. Wolverine Asset Management LLC purchased a new stake in shares of KalVista Pharmaceuticals during the third quarter valued at $57,000. KLP Kapitalforvaltning AS purchased a new stake in shares of KalVista Pharmaceuticals during the third quarter valued at $63,000. Finally, Truvestments Capital LLC boosted its position in shares of KalVista Pharmaceuticals by 253.8% in the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company's stock valued at $76,000 after purchasing an additional 3,360 shares during the period.

KalVista Pharmaceuticals Price Performance

The stock has a 50 day moving average of $15.87 and a two-hundred day moving average of $14.41. The stock has a market cap of $946.55 million, a PE ratio of -4.74 and a beta of -0.35. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm's scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista's approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company's lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.